A Prospective, Open-label, Single-arm, Multicenter Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia

Schizophrenia is a long-lasting and serious mental health disorder that affects about 1% of people worldwide. It can cause symptoms such as hallucinations and delusions (called positive symptoms), confused or disorganized thinking, reduced motivation and emotional expression (negative symptoms), difficulties with memory and concentration (cognitive symptoms), and movement problems like restlessness or slowed activity. Current treatments, called antipsychotics, mainly work by blocking dopamine in the brain. These medicines are helpful for hallucinations and delusions, but they do little to improve negative or cognitive symptoms.
A new medicine, Xanomeline/Trospium (XT), works differently. It targets a brain system called the muscarinic acetylcholine receptors while limiting side effects elsewhere in the body. Clinical trials have shown that XT reduces psychotic symptoms effectively and is generally well tolerated. The FDA approved XT in 2024 for adults with schizophrenia. Importantly, early results also suggest that XT may help improve thinking and memory (cognition domains), though this has not yet been studied in depth.
Most schizophrenia drug studies pay little attention to long-term changes in cognition, often using only short screening tests. This study will be the first to take a deep look at cognitive function over a full year of XT treatment. It will also examine how changes in thinking skills connect with other aspects of life, such as symptom control, daily functioning, and quality of life. By making cognition a central outcome, the study responds to an urgent need in schizophrenia research: moving beyond just controlling hallucinations and delusions toward improving real-world recovery. The results could help shape future treatment strategies and support the idea that cognition should be a core treatment target in schizophrenia.

Start Date31 Dec 2026

Sponsor / Collaborator

Bristol Myers Squibb Co.

NCT07228338

/ Not yet recruitingEarly Phase 1IIT

Muscarinic Agonist Modulation of Memory Processing Oscillatory Activity

The goal of this study is to learn about the effects of Cobenfy KarXT (xanomeline and trospium chloride) on episodic memory processing, including specific effects on areas of the brain involved in memory and changes it may have on brain activity. The investigators will do this by testing epileptic patients who are already undergoing intracranial surgery for seizure monitoring, and measuring the activity from the brain areas being assessed.
The main questions it aims to answer are 1) whether Cobenfy KarXT changes memory activity based on its agonist effect on muscarinic receptors and acetylcholine, and 2) what the nature of these brain activity changes are. This work builds on previous experiments evaluating cholinergic antagonists.
Participants will complete two treatment arms. One of these will be with the drug, and the other will be with a placebo pill, so that the participants are unaware which session the actual drug has been received. Patients will complete a verbal serial recall and/or associative recognition task each of the two days. An anesthesiologist or patient nurse will administer either the drug or the placebo at a critical point which addresses both of the research questions.
Researchers will compare the brain activity between the two treatment arms to determine what brain activity changes, and whether there is an additional behavioral effect on memory.

Start Date30 Sep 2026

Sponsor / Collaborator

The University of Texas Southwestern Medical Center

NCT07285798

/ Not yet recruitingPhase 3

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of KarXT + KarX-EC in Children and Adolescents (5 to 17 Years of Age) With Irritability Associated With Autism Spectrum Disorder

The purpose of this study is to assess KarXT + KarX-EC for the treatment of irritability associated with autism in children and adolescents.

Start Date10 Sep 2026

Sponsor / Collaborator

Bristol Myers Squibb Co.

100 Clinical Results associated with Xanomeline Tartrate/Trospium Chloride

100 Translational Medicine associated with Xanomeline Tartrate/Trospium Chloride

100 Patents (Medical) associated with Xanomeline Tartrate/Trospium Chloride

Literatures (Medical) associated with Xanomeline Tartrate/Trospium Chloride

01 Jul 2026·PSYCHIATRY RESEARCH

A real-world pharmacovigilance study of Xanomeline-Trospium events in the FDA adverse event reporting system (FAERS)

Article

Author: Lin, Haiyan ; Qian, Hong ; Feng, Tianpu ; Ji, Jing ; Song, Xiaoxue

BACKGROUND:

Xanomeline-Trospium (Cobenfy®) improves cognitive function in schizophrenia, yet its post-marketing reporting patterns remain incompletely characterized. This hypothesis-generating pharmacovigilance study explores adverse event associations during its first year on market.

OBJECTIVE:

To characterize disproportionate reporting patterns and generate hypotheses for clinical monitoring strategies, acknowledging the inherent limitations of spontaneous reporting data.

METHODS:

Adverse event reports from Q4 2024-Q3 2025 were analyzed using disproportionality methods (ROR, PRR, BCPNN) and temporal distribution analysis. A dual-track approach incorporated both statistical signal detection (n ≥ 3) and descriptive surveillance of rare serious events (n < 3).

RESULTS:

Of 1142 reports, urinary and neurological events exhibited the strongest statistical disproportionality: urinary retention (ROR=45.63, 95% CI: 35.97-57.87) and hypersalivation (ROR=64.39, 95% CI: 43.25-95.85). Psychiatric events were frequently reported but showed weaker specificity, likely reflecting disease confounding rather than drug-induced effects. Treatment non-adherence showed elevated reporting (ROR=7.58), potentially associated with psychiatric symptomatology. Time-to-onset analysis suggested acute-phase reporting concentration (median 2 days; 45.4% of non-day-0 events occurring within days 1-7).

CONCLUSION:

These findings suggest disproportionate reporting patterns for urinary, neurological, and psychiatric events associated with Xanomeline-Trospium. While these signals warrant further validation through prospective cohort studies, they offer complementary real-world context for clinical decision-making. Active monitoring during initial treatment weeks may be prudent, particularly among patients with renal impairment or concomitant anticholinergic use.

01 Jun 2026·SCHIZOPHRENIA RESEARCH

Low incidence of extrapyramidal symptoms following treatment with a muscarinic agonist medication for schizophrenia

Review

Author: Marcus, Ronald ; Lin, Wei-Chih ; Watson, Carolyn ; Targum, Steven D ; Novak, Keisha D ; Kaul, Inder ; Claxton, Amy ; Nicolas, Pierre ; Marder, Stephen R ; Brannan, Stephen K ; Horan, William P

BACKGROUND:

Extrapyramidal symptoms (EPS) have long been associated with the use of antipsychotic medications. The etiology of EPS has often been attributed to dopamine D₂ receptor antagonism. Most currently available antipsychotics bind to the D₂ receptor, albeit with different affinities, and consequently yield different EPS risk. Some novel medications for schizophrenia do not directly affect dopaminergic systems at all. For instance, xanomeline, a preferential M₁ and M₄ muscarinic receptor agonist combined with trospium chloride (KarXT) is approved for the treatment of schizophrenia and has shown a lower EPS liability.

METHODS:

We conducted a comprehensive review of the cumulative data regarding the occurrence of EPS in several studies of KarXT in schizophrenia that included 3 double-blind, placebo-controlled hospital-based studies and 2 open-label outpatient studies. We also tracked the progression of EPS in a small subgroup of study participants who presented with EPS prior to randomization.

RESULTS:

A small proportion of individuals receiving KarXT reported EPS-related treatment-emergent adverse events (3.8% in the 3 combined double-blind studies and 2.6% in 2 open-label studies), and most instances were not considered study drug-related. Akathisia occurred in 2.4% of participants receiving KarXT in the double-blind studies, but only 0.6% of cases were attributed to KarXT, and most resolved within 1 day without concomitant medication. Further, preexisting EPS identified by EPS scales before initiating KarXT treatment, particularly akathisia, attenuated during the studies.

CONCLUSIONS:

Non-dopamine-focused medications like KarXT offer an effective, alternative treatment for schizophrenia with minimal EPS liability that may benefit individuals who require these medications.

02 May 2026·BMC Psychiatry

Transitioning from clozapine to Cobenfy (xanomeline-trospium chloride) in treatment resistant schizophrenia and clozapine induced OCD.

Article

Author: Lewis, Stephen F ; Rose, Rachel M ; Nakip, Ali

BACKGROUND:

Treatment-resistant schizophrenia (TRS) is defined as nonresponse to at least two adequate antipsychotic trials at therapeutic doses for six or more weeks. Currently, clozapine is the only antipsychotic approved for TRS by the FDA and a plethora of evidence indicates that it is the most efficacious antipsychotic for treatment of chronic and refractory cases of schizophrenia. However, its utilization is often limited by metabolic, hematologic, and anticholinergic side effects. Notably, clozapine-induced obsessive-compulsive symptoms (OCS) or obsessive-compulsive disorder (OCD) have been increasingly recognized, attributed to its potent serotonergic antagonism. In 2024, the FDA approved xanomeline-trospium, a dual agent combining a central muscarinic M1/M4 agonist with a peripheral antimuscarinic, which offers a novel approach to treating psychosis. Early evidence suggests comparable efficacy to other antipsychotics, with fewer metabolic and extrapyramidal side effects. We present a case of a woman with longstanding schizophrenia and clozapine-induced OCD successfully transitioned to xanomeline-trospium, resulting in remission of both psychotic and obsessive-compulsive symptoms.

CASE PRESENTATION:

A 57-year-old woman with a chronic history of schizophrenia, requiring multiple hospitalizations and maintenance electroconvulsive therapy (ECT), stabilized on clozapine 300 mg nightly after failing several antipsychotics. Despite adherence, she exhibited persistent hallucinations, negative symptoms, and later developed clozapine-induced OCD characterized by intrusive counting and numerical obsessions refractory to high-dose sertraline. Due to distressing OCD and passive suicidal ideation, she was admitted for a discontinuation of clozapine and initiation of xanomeline-trospium. Clozapine was tapered and discontinued before initiating xanomeline-trospium, titrated to 100 mg/20 mg twice daily. Within one week after starting xanomeline-trospium, her counting obsessions resolved, psychosis improved, and suicidality resolved. At discharge, three weeks post-admission, she remained stable on xanomeline-trospium, ziprasidone, and sertraline, with complete remission of hallucinations and obsessions.

CONCLUSION:

This case highlights a successful switch from clozapine to xanomeline-trospium for management of chronic schizophrenia and clozapine induced OCD. The patient's improvement raises important considerations regarding clozapine-induced OCD, cautious discontinuation, and the benefit of muscarinic receptor agonists. Xanomeline-trospium may represent a viable alternative for patients intolerant of clozapine.

CLINICAL TRIAL NUMBER:

Not applicable.

353

News (Medical) associated with Xanomeline Tartrate/Trospium Chloride

27 May 2026

·www.biospace.com

Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors

Miller brings deep neuropsychiatry drug development and value creation experience, having led R&D at Karuna Therapeutics through its $14 billion acquisition by Bristol Myers Squibb MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- $anro #cns --Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Andrew Miller, Ph.D. to its Board of Directors, effective May 27, 2026. “We are thrilled to welcome Andrew to Alto’s Board at a transformative time for the Company,” said Amit Etkin, M.D., Ph.D., Founder and Chief Executive Officer of Alto Neuroscience. “Few leaders in our industry have done more to advance the science and commercial reality of new medicines for serious mental illness. Andrew’s firsthand experience translating novel neuropsychiatric mechanisms into approved therapies — and building a category-defining company around them — will be invaluable as we execute on our potentially pivotal Phase 2b trial of ALTO-207 in treatment-resistant depression and advance multiple additional readouts across our precision psychiatry pipeline.” “Psychiatry remains one of the largest areas of unmet medical need in all of healthcare. Far too many patients with depression, schizophrenia, and other serious mental illnesses are left without treatments that truly work for them,” said Dr. Miller. “Alto’s pipeline reflects a clear-eyed focus on changing that — advancing novel mechanisms with the potential to deliver substantially better outcomes. I’m honored to join the Board and look forward to helping the team realize that vision for patients.” Dr. Miller is a highly accomplished biopharmaceutical executive with expertise in neuropsychiatric drug development, corporate strategy, and value creation. Most recently, he was the Founder and President of R&D at Karuna Therapeutics, where he was the lead inventor of KarXT — now marketed by Bristol Myers Squibb as COBENFY® for the treatment of schizophrenia, the first novel mechanism approved in the indication in decades. He previously served as Karuna’s Chief Operating Officer, Chief Executive Officer, and as a member of its Board of Directors, guiding the company through its $14 billion acquisition by Bristol Myers Squibb in 2024. Dr. Miller was named to Time magazine’s 100 Next Generation Leaders and 100 Most Influential People in Healthcare for 2025. Dr. Miller currently serves as Chairman of the Board of Progentos Therapeutics and a member of the Board of Montara Therapeutics and as an advisor to GV (Google Ventures), General Atlantic, Vida Ventures, Longwood Fund, and the One Mind Foundation. He holds a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology and a B.S. in Chemical Engineering from the University of Illinois at Urbana-Champaign. About Alto Neuroscience Alto Neuroscience, Inc. (NYSE: ANRO) is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto’s product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in treatment-resistant depression, major depressive disorder, bipolar depression, schizophrenia, and other mental health conditions. For more information, visit or follow Alto on X. Forward-Looking Statements This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “expects,” “plans,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding Alto’s expectations about the potential benefits, activity, effectiveness and safety of its product candidates and Precision Psychiatry Platform (“Platform”); and Alto’s expectations with regard to the design, timing, and results of its clinical trials. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including uncertainties inherent in the initiation, progress and completion of clinical trials and other important factors, any of which could cause Alto’s actual results to differ from those contained in the forward-looking statements, which are described in greater detail in the section titled “Risk Factors” in Alto’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the Securities and Exchange Commission (“SEC”) as well as in other filings Alto may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alto expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as required by law. Contacts Investor & Media Contact Nick Smith Investors@altoneuroscience.com

21 May 2026

·www.biospace.com

Zai Lab Announces Changes to Senior Leadership Team - May 21, 2026

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced changes to its senior leadership team aimed at strengthening operational performance and efficiency. As part of these changes, the Board has made the decision that Josh Smiley, President and COO, will no longer be with the Company, effective Friday, May 22. "I want to thank Josh for his contributions to Zai Lab over the past three and a half years and wish him well in his future endeavors," said Samantha Du, Founder, Chairperson and Chief Executive Officer of Zai Lab. Zai Lab anticipates multiple clinical data readouts in 2026 for its lead global investigational therapies, including zoci in first-line ES-SCLC and extrapulmonary NECs, and ZL-1503 (IL-13/IL-31Rα), with a first-in-human data readout from the global Phase 1/1b study. The company is also preparing for the launch of COBENFY™ in China and for multiple anticipated regional regulatory approvals and expected data readouts. About Zai Lab Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health. For additional information about Zai Lab, please visit or follow us at . Zai Lab Forward-Looking Statements This press release contains certain forward-looking statements, including statements relating to our strategy and plans; potential of and expectations for our business, commercial products, and pipeline programs; clinical development programs and related clinical trials; clinical trial data, data readouts, and presentations; risks and uncertainties associated with drug development and commercialization; regulatory discussions, submissions, filings, and approvals and the timing thereof; the potential benefits, safety, and efficacy of our products and product candidates and those of our collaboration partners; the anticipated benefits and potential of investments, collaborations, and business development activities. All statements, other than statements of historical fact, included in this press release are forward-looking statements, and can be identified by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “poised,” “positioned,” “possible,” “potential,” “will,” “would,” and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. We may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in our forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products; (2) our ability to obtain funding for our operations and business initiatives; (3) the results of our clinical and pre-clinical development of our product candidates; (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates; (5) risks related to doing business in China; and (6) other factors identified in our most recent annual and quarterly reports and in other reports we have filed with the U.S. Securities and Exchange Commission (SEC). We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Our SEC filings can be found on our website at and on the SEC’s website at . Contacts For more information, please contact: Investor Relations: Christine Chiou / Cyan Liu +1 (917) 886-6929 / +86 195 3130 8895 christine.chiou1@zailaboratory.com / cyan.liu@zailaboratory.com Media: Shaun Maccoun / Xiaoyu Chen +1 (857) 270-8854 / +86 185 0015 5011 shaun.maccoun@zailaboratory.com / xiaoyu.chen@zailaboratory.com

Executive Change

20 May 2026

·ir.zailaboratory.com

Zai Lab Announces Changes to Senior Leadership Team

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 21, 2026-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced changes to its senior leadership team aimed at strengthening operational performance and efficiency. As part of these changes, the Board has made the decision that Josh Smiley, President and COO, will no longer be with the Company, effective Friday, May 22. "I want to thank Josh for his contributions to Zai Lab over the past three and a half years and wish him well in his future endeavors," said Dr. Samantha Du, Founder, Chairperson and Chief Executive Officer of Zai Lab. Zai Lab anticipates multiple clinical data readouts in 2026 for its lead global investigational therapies, including zoci in first-line ES-SCLC and extrapulmonary NECs, and ZL-1503 (IL-13/IL-31Rα), with a first-in-human data readout from the global Phase 1/1b study. The company is also preparing for the launch of COBENFY™ in China and for multiple anticipated regional regulatory approvals and expected data readouts. About Zai Lab Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health. For additional information about Zai Lab, please visit www.zailaboratory.com or follow us at https://x.com/ZaiLab_Global. Zai Lab Forward-Looking Statements This press release contains certain forward-looking statements, including statements relating to our strategy and plans; potential of and expectations for our business, commercial products, and pipeline programs; clinical development programs and related clinical trials; clinical trial data, data readouts, and presentations; risks and uncertainties associated with drug development and commercialization; regulatory discussions, submissions, filings, and approvals and the timing thereof; the potential benefits, safety, and efficacy of our products and product candidates and those of our collaboration partners; the anticipated benefits and potential of investments, collaborations, and business development activities. All statements, other than statements of historical fact, included in this press release are forward-looking statements, and can be identified by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “poised,” “positioned,” “possible,” “potential,” “will,” “would,” and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. We may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in our forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products; (2) our ability to obtain funding for our operations and business initiatives; (3) the results of our clinical and pre-clinical development of our product candidates; (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates; (5) risks related to doing business in China; and (6) other factors identified in our most recent annual and quarterly reports and in other reports we have filed with the U.S. Securities and Exchange Commission (SEC). We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Our SEC filings can be found on our website at www.zailaboratory.com and on the SEC’s website at www.SEC.gov. View source version on businesswire.com: https://www.businesswire.com/news/home/20260521314535/en/ For more information, please contact: Investor Relations: Christine Chiou / Cyan Liu +1 (917) 886-6929 / +86 195 3130 8895 christine.chiou1@zailaboratory.com / cyan.liu@zailaboratory.com Media: Shaun Maccoun / Xiaoyu Chen +1 (857) 270-8854 / +86 185 0015 5011 shaun.maccoun@zailaboratory.com / xiaoyu.chen@zailaboratory.com Source: Zai Lab Limited

Executive Change

100 Deals associated with Xanomeline Tartrate/Trospium Chloride

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Schizophrenia	United States	Bristol Myers Squibb Co.	26 Sep 2024

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Autistic Disorder	Phase 3	United States	Bristol Myers Squibb Co.	11 Sep 2026
Autistic Disorder	Phase 3	Argentina	Bristol Myers Squibb Co.	11 Sep 2026
Autistic Disorder	Phase 3	Australia	Bristol Myers Squibb Co.	11 Sep 2026
Autistic Disorder	Phase 3	Canada	Bristol Myers Squibb Co.	11 Sep 2026
Autistic Disorder	Phase 3	India	Bristol Myers Squibb Co.	11 Sep 2026
Irritable Mood	Phase 3	United States	Bristol Myers Squibb Co.	11 Sep 2026
Irritable Mood	Phase 3	Japan	Bristol Myers Squibb Co.	11 Sep 2026
Irritable Mood	Phase 3	Argentina	Bristol Myers Squibb Co.	11 Sep 2026
Irritable Mood	Phase 3	Australia	Bristol Myers Squibb Co.	11 Sep 2026
Irritable Mood	Phase 3	Canada	Bristol Myers Squibb Co.	11 Sep 2026

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05145413 (ARISE \| KAR-012, CTgov)	Phase 3	Schizophrenia	396	Placebo	tspygekdhf(nzfkcsphnp) = avyjfycprv nphsarjanr (heorfxphnf, 0.98) View more	-	05 May 2026
NCT05919823 (UNITE-001 \| ZL-2701-001, CTgov)	Phase 3	Schizophrenia	202	trospium+KarXT+xanomeline (Double-Blind Part: KarXT)	nahyzqfxfy(yhqbeapvet) = hpxfolyeag xruhzfkpni (wrctiegyqt, 2.122) View more	-	21 Nov 2025
				placebo+KarXT (Double-Blind Part: Placebo)	nahyzqfxfy(yhqbeapvet) = uzffrynwsb xruhzfkpni (wrctiegyqt, 2.074) View more
NCT04820309 (EMERGENT-5, CTgov)	Phase 3	Schizophrenia	566	Xanomeline and Trospium Chloride Capsules	dlgzcszgdo = ggqwmebhro ulwfptkxda (ieiqxzwngl, kzsqydvitv - dnpywrbixl) View more	-	17 Sep 2025
NCT05145413 (ARISE \| KAR-012, Company_Website) Manual	Phase 3	Schizophrenia	-	Cobenfy + APD (mITT)	pizizseaqt(wdonugnnxu) = zoxuwsnhwm pmfcfjldrr (zatsblkuyt, 1.01) Not Met View more	Negative	22 Apr 2025
				Placebo + APD (mITT)	pizizseaqt(wdonugnnxu) = hqhfrcgnkh pmfcfjldrr (zatsblkuyt, 0.98) Not Met View more
NCT04738123 \| NCT04659161 \| NCT03697252 (EMERGENT-2, Pubmed \| J Clin Psychiatry)	Not Applicable	Schizophrenia	683	Xanomeline/Trospium	wjsdeiavdr(zvdvcmtriz) = xotzsvqdsy lqwxjolysc (wbjzwizbkj ) View more	Positive	26 Feb 2025
				Placebo	wjsdeiavdr(zvdvcmtriz) = acgccsnudv lqwxjolysc (wbjzwizbkj ) View more
NCT04738123 (EMERGENT-3 \| EMERGENT-1, EMERGENT-2, EMERGENT-3, CTgov)	Phase 3	Schizophrenia	256	Xanomeline and Trospium Chloride Capsules (KarXT)	cjlkfnqzhr(mfzhejjxum) = ohjircffrb yhhmcpwwpc (obnyggxxri, 1.584) View more	-	09 Dec 2024
				Placebo (Placebo)	cjlkfnqzhr(mfzhejjxum) = tuffxqatou yhhmcpwwpc (obnyggxxri, 1.552) View more
NCT04820309 (EMERGENT-5, Company_Website) Manual	Phase 3	Schizophrenia	566	COBENFY	telmpklmbk(nofohowexw) = wpnnyyjvmw lpnhxgvkcb (hgnexwwgeg ) View more	Positive	31 Oct 2024
NCT04659174 (EMERGENT-4, Company_Website) Manual	Phase 3	Schizophrenia	156	COBENFY	vepqyflcdu(gkpffghsjo) = obfpjyhbnz xcyqvyrzbz (tlfiecevvt )	Positive	31 Oct 2024
				Placebo	-
NCT05919823 (ZL-2701-001, NEWS) Manual	Phase 3	Schizophrenia	202	KarXT	azypaljcja(jwomlslppm) = fmbtmbvcto hzcihbgosk (najrpyrhco ) Met View more	Positive	29 Oct 2024
				Placebo	azypaljcja(jwomlslppm) = pgythacgyn hzcihbgosk (najrpyrhco ) Met View more
NCT04659174 (EMERGENT-4, CTgov)	Phase 3	Schizophrenia	152	KarXT (KarXT Arm A)	plqxsxfvdc = qwkskbgrjr awewlcbkxb (pzdywqlqrr, kggqubflby - kiisxivzxi) View more	-	28 Oct 2024
				Placebo+KarXT (KarXT Arm B)	plqxsxfvdc = dovofimgml awewlcbkxb (pzdywqlqrr, gvhpddtdgt - iumrgaujae) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Xanomeline Tartrate/Trospium Chloride

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation